Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00501332
Status:
UNKNOWN
Last Update Posted:
2007-12-24
First Post:
2007-07-12
Brief Title:
Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC Docetaxel Adriamycin Cyclophosphamide Chemotherapy
Sponsor:
Maxygen Holdings Ltd
Organization:
Maxygen Holdings Ltd
Study Overview
Official Title:
A Phase IIa Open Label Controlled Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I II or IIIa Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2007-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an investigation of the safety and efficacy of Maxy-G34 in breast cancer patients treated with TAC chemotherapy Maxy-G34 will be given as a single injection during each cycle of chemotherapy for a planned total of six chemotherapy cycles
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT No 2006-006565-16 | None | None | None |
| PAREXEL 84728 | None | None | None |